PEPTONIC medical today announced the tentative program for company presentations during the subscription period for the rights issue in connection with the planned listing (IPO) on Aktietorget Stock Exchange (Stockholm)
PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.
The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.
Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.
PEPTONIC medical AB (publ)
SE-167 51 Bromma